EU Device Supply Interruption Notices: Who Must Pass Them On?

Imagine an EU medical device distributor opening an email from an overseas factory's European master importer. The letter states that a sterile urology consumable the distributor supplies to fifteen regional surgical centers will be permanently discontinued in seven months. In the same week, another supplier sends a routine operations email stating that a specialized catheter line is backordered for ten weeks due to sterilization chamber maintenance. Which of these messages triggers a mandatory regulatory reporting cascade to hospital procurement teams, who must execute that relay, how fast must it occur, and what documentation protects the distributor during a competent authority inspection?

Until recently, EU medical device legislation contained no harmonized requirement for warning healthcare systems of impending supply disruptions. While the pharmaceutical sector had long operated under mandatory shortage notification rules, device manufacturers and distributors handled product discontinuations through disparate commercial channels. That landscape shifted fundamentally when the European Union enacted Regulation (EU) 2024/1860⁷ on 13 June 2024, inserting Article 10a into both the Medical Device Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR)⁸.

Applicable since 10 January 2025, Article 10a is widely discussed in industry circles as an obligation on medical device manufacturers. However, ranking consultancy summaries and trade explainers routinely overlook the critical downstream obligation codified in Article 10a(3): any economic operator that receives supply interruption information from a manufacturer or an upstream supplier has an independent statutory duty to relay that information forward. For importers, wholesale distributors, and procedure-pack assemblers, understanding this relay mechanism is essential to avoid non-compliance, preserve customer trust, and protect patient safety. The Commission published Revision 2 of its Article 10a Q&A on 1 April 2026² and lists it on its MDCG guidance page alongside the MDCG 2024-16 manufacturer form, the form's Annex for reports covering several devices, and the CAMD decision tree^{3, 4, 6}.

Is this supplier message an Article 10a notice or just a backorder?

The first operational challenge facing a distributor is categorizing incoming communications. Medical device supply chains experience daily logistical friction—raw material shortages, customs holds, packaging re-runs, and transit delays. Not every commercial backorder is an Article 10a event, and misclassifying routine delays as statutory public health notifications causes unnecessary clinical alarm. Conversely, failing to recognize an authentic Article 10a communication risks breaching the distributor's own duty under Article 10a(3)⁷.

Article 10a(1) applies when a manufacturer anticipates an interruption or discontinuation of supply and it is reasonably foreseeable that this could result in serious harm or a risk of serious harm to patients or public health in one or more Member States⁷. The Commission Q&A and the CAMD decision tree break the manufacturer's assessment into three practical questions:

1. Anticipated interruption or discontinuation: The manufacturer foresees either a temporary inability to place the device model or type on the Union market or a permanent cessation of supply. Under Question 7 of the European Commission's Questions and Answers guidance (Rev.2, published April 2026)¹, an interruption is generally indicated as a temporary inability expected to last more than 60 days. The figure is a general indication, not a hard threshold: a shorter interruption can still fall within scope where the manufacturer assesses that it may result in serious harm.
2. Foreseeable serious harm or risk of serious harm: It must be reasonably foreseeable that the supply disruption may result in serious harm or a risk of serious harm to patients or public health in one or more Member States. As defined in Q&A Questions 9 and 9.1¹ and Notes 4 and 5 of the Competent Authorities for Medical Devices (CAMD) Decision Tree (April 2026)⁵, serious harm includes situations where patients face an imminent risk of death, a serious deterioration of health or a life-threatening condition, and no suitable alternative diagnosis method or therapy is available.
3. Alternatives and stock: In principle, the Q&A says no notice is needed where the manufacturer replaces the device with a successor intended to be used alternatively, holds a stockpile that bridges the interruption, or has been told by health institutions or healthcare professionals that a suitable alternative meeting expected demand exists. The decision tree also asks whether an alternative from another manufacturer is available and can meet expected demand or clinical needs^{1, 5}.

The assessment belongs to the manufacturer (Q&A questions 3 and 9.1)¹. Importers and distributors do not make it or override it. That has a practical consequence: there is no EU template for the downstream message, so you need a way to recognize one. A sales representative's note that 'Item X is out of stock until next month' is not an Article 10a notice. Markers that usually indicate one include an explicit reference to Article 10a, identification of the legal manufacturer and the affected models (often with Basic UDI-DI or UDI-DI), the anticipated start date (and expected end date for an interruption), and a statement that the competent authority has been informed. MDCG 2024-16 is the authority-facing form³; a manufacturer is not required to send it to you. If a message is ambiguous, ask the sender in writing whether it is the manufacturer's Article 10a information, and record the answer.

Who has to tell whom, and when, from manufacturer to hospital?

Article 10a establishes a multi-tiered information cascade designed to ensure that supply disruption warnings reach the clinicians and health institutions delivering patient care. The structure spans four distinct operational layers:

1. The legal manufacturer (EU or non-EU): Under Article 10a(1)⁷, the manufacturer must inform (a) the competent authority of the Member State where it or its authorised representative is established and (b) the economic operators, health institutions and healthcare professionals to whom it directly supplies the device. Other than in exceptional circumstances (for example a natural disaster or a sudden inability to obtain raw materials or components), the information must be provided at least six months before the anticipated interruption or discontinuation; in exceptional circumstances the Q&A expects it without undue delay^{1, 5}. Under Article 10a(2), the competent authority then informs the other Member States and the Commission.
2. The EU Importer: Where a non-EU manufacturer sells through an EU importer, the manufacturer notifies the importer as a directly supplied economic operator. Under Article 10a(3), the importer cannot retain this information internally; it must forward the notice without undue delay to all distributors and healthcare institutions it directly supplies.
3. The Wholesale / Sub-Distributor: Distributors who receive the notice from an importer or another distributor must forward it without undue delay to other distributors, hospitals, surgical clinics, and healthcare practitioners to whom they directly supply the device.
4. The Health Institutions & Healthcare Professionals: The terminal recipients in the cascade. Hospitals use the advance warning to review clinical protocols, evaluate alternative CE-marked consumables, and initiate emergency tendering or product adoption.

Notice what is absent from Table 2: Article 10a gives distributors and importers no duty to notify a competent authority. That notification belongs to the manufacturer and goes to the authority where it or its authorised representative is established; that authority then informs the other Member States and the Commission under Article 10a(2)⁷. Member States may publish additional submission instructions (Q&A question 11)¹, but contacting an authority is never a substitute for the downstream relay.

How fast must a distributor forward the notice, and may it be edited?

Two questions repeatedly arise in distributor quality departments: exactly how much time does 'without undue delay' permit, and can the distributor edit, summarize, or translate the manufacturer's notice?

Question 13 of Commission Q&A Rev.2¹ explains that, for the purposes of that document, 'without undue delay' means acting as soon as possible and without any delay intentionally or negligently caused by the economic operator. In practice, a notice cannot wait for a quarterly newsletter or the next sales visit. Neither the Regulation nor the Q&A sets a numeric window, so write your own internal target into the SOP, measure it from documented receipt, and record the reason whenever it is exceeded (for example, time needed to confirm the recipient list).

Crucially, distributors must recognize that the statutory six-month advance notice clock binds only the manufacturer. If a manufacturer experiences an exceptional supply breakdown and issues a notice with three months' lead time, or if an upstream importer takes two weeks to process a notice, the downstream distributor is not answerable for the six-month rule. The distributor's sole statutory duty is to forward what it received, without undue delay, from the date of its own receipt¹.

On editing, the Q&A is clear in substance, although it uses guidance language rather than the Regulation's 'shall'. Question 2 says notified operators cascade the information 'as provided by the manufacturer (without changing, adding to or paraphrasing this communication so as to preserve its integrity)', and Question 13 says it is expected that economic operators 'do not change, add to or paraphrase the communication received from the manufacturer'¹. The relay duty itself comes from the Regulation⁷:

The economic operators who have received the information from the manufacturer in accordance with paragraph 1 or from another economic operator in the supply chain shall, without undue delay, inform any other economic operators, health institutions and healthcare professionals to whom they directly supply the device, of the anticipated interruption or discontinuation.— Article 10a(3) MDR, as inserted by Regulation (EU) 2024/1860

Why preserve the original? Exact wording carries the scope of the notice. A distributor's own summary can drop affected catalogue numbers, model or lot boundaries, dates or the manufacturer's suggested mitigation. If a customer later relies on an incomplete summary, the distributor will struggle to show that it passed on the manufacturer's communication as received.

Can a distributor attach its own commercial message? Yes, as a separate document. For example: 'Please find attached, unchanged, the MDR Article 10a supply interruption notice issued by Manufacturer X for Catheter Line Y. Catheter Line Z, which has a similar intended purpose, is available from our warehouse; please assess its suitability with your clinical team.' What the distributor should not do is replace the manufacturer's document with its own memo, edit its text, or present an alternative as equivalent without evidence.

A subtle unresolved issue concerns language. Q&A Rev.2 does not say whether a notice may or must be translated before it is passed on¹. Article 14(2) requires distributors to verify that a device is accompanied by the manufacturer's information in the required languages, but that provision concerns labels and instructions for use, not supply notices⁸. The cleanest route is to ask the manufacturer to issue its notice in the languages your customers need, so every version is the manufacturer's own communication. Where that is not possible and a customer or national rule requires a translation, forward the original unchanged and attach a translation clearly labelled as the distributor's courtesy translation.

Whom exactly do you forward it to, and where does that list come from?

Distributors frequently ask: must we blast the notice to every healthcare facility in our contact database, or only to existing accounts? And how far back in our sales history must we look?

The statutory answer is rooted in MDR Article 25(2) (Traceability)⁸. Under Article 25(2), economic operators must be able to identify: (a) any economic operator to whom they have directly supplied a device; and (b) any health institution or healthcare professional to whom they have directly supplied a device. Question 13 of Commission Q&A Rev.2 recalls these Article 25(2) records in the context of the relay¹.

Your legal obligation is strictly bounded by direct supply relationships. You are not required to notify hospitals supplied by competing distributors, nor are you required to notify institutions that have never purchased the affected SKU from your firm. To construct an auditable recipient roster:

1. Query ERP / Billing Records: Filter sales ledgers for the specific device trade name, catalog reference, and Basic UDI-DI / UDI-DI identified in the manufacturer's notice.
2. Define and document a lookback window: Article 10a(3) refers to those to whom you directly supply the device, and the Q&A (question 4, written for manufacturers) treats actors whose supply had already ceased as not impacted^{1, 7}. Neither text sets a period. For sterile single-use consumables, a defensible internal rule is to include customers that bought the device recently enough that they may still hold stock or rely on reorders (for example, within the labelled shelf life) and to record that rule in the SOP. For durable equipment, consider the installed base still in service.
3. Capture Sub-Distributor Accounts: If your firm acts as a master distributor or wholesaler selling to regional sub-dealers, those sub-dealers must be included as directly supplied economic operators so they can trigger their own downstream relay.
4. Record Verified Points of Contact: Direct the notice to hospital procurement directors, materials management, surgical department heads, and relevant clinical engineering teams, logging delivery receipts and transmission timestamps.

What changes when the device sits inside a procedure pack?

A specialized scenario arises when an interrupted or discontinued device is incorporated into a system or procedure pack under MDR Article 22⁸. Many hospitals buy sterile single-use consumables inside procedure packs (for example urology, laparoscopy or catheterization trays) rather than as individual items.

Question 14 of Commission Q&A Rev.2¹ says Article 10a(1) applies to the manufacturers of individual CE-marked devices within a system or procedure pack, who inform the competent authority and the pack producer. On receipt, the pack producer must, under Article 10a(3) and without undue delay, transmit the information to the operators, health institutions and healthcare professionals it directly supplies. The Q&A does not make that relay conditional on whether the finished pack will be affected. A pack producer will usually also want to tell customers whether and when pack supply changes, but that is its own message, kept separate from the manufacturer's notice. For pack-level obligations more broadly, see our companion guide on how EU MDR Article 22 procedure packs are regulated.

A parallel risk involves system-dependent consumables. When a single-use consumable works only with one generator, laser console or pump, switching brands may not be possible without changing the hardware. Section 7 of MDCG 2024-16³ includes an assessment option for a 'consumable device not replaceable by any other type/brand', and the CAMD decision tree⁵ routes cases with no alternative in the manufacturer's portfolio or from another manufacturer toward the serious-harm question, noting that an alternative needing particular infrastructure or training may be of limited use. For why proprietary interfaces limit substitution, see our evaluation of why NPWT dressing kits are not interchangeable across pumps.

What changes when the manufacturer is outside the EU?

Many sterile surgical consumables, urological devices and perioperative products placed on the EU market originate from manufacturers in China, the United States, or other non-EU countries. When the legal manufacturer is established outside the Union, specific regulatory mechanisms apply¹:

• Competent authority notification point: Under Article 10a(1), a non-EU manufacturer informs the competent authority of the Member State where its authorised representative (EC REP) is established. If a Chinese manufacturer's authorised representative is established in Germany, for example, the form goes to the German competent authority, following any submission instructions that authority publishes^{1, 3}.
• Non-Delegable Legal Responsibility: Commission Q&A Rev.2 Question 2 clarifies that while a non-EU manufacturer may entrust practical submission tasks to its EC REP, importer, or regulatory consultant, legal responsibility for compliance remains strictly with the manufacturer.
• The Importer as First Relay Point: The non-EU manufacturer informs the EU importers it directly supplies. The importers then initiate the downstream relay across the European distribution network under Article 10a(3).

In Question 4 of Q&A Rev.2¹, the Commission walks through this relay for a CE-marked pacemaker from a non-EU manufacturer. The re-expression below is hypothetical. It assumes the manufacturer has concluded that the interruption could cause serious harm, for example because the consumable works only with an installed system and no alternative can meet demand. Many commodity consumables will not meet that test.

What should a distribution agreement add that the law does not?

Article 10a improves visibility of serious supply problems, but distributors should understand its commercial limits. It leaves significant gaps.

Specifically, Article 10a applies only where it is reasonably foreseeable that the interruption or discontinuation could result in serious harm, a judgment the manufacturer makes. If a manufacturer decides to discontinue a low-margin consumable because commercial returns are inadequate, but concludes that competing brands can absorb hospital demand, the manufacturer may take the position that Article 10a does not apply. In that scenario, the manufacturer has no statutory obligation to provide six months' advance notice under EU law^{1, 5}.

Likewise, a 45-day interruption is below the Q&A's 60-day general indication and, for most devices with available alternatives, will not produce a notice¹. Yet for a distributor bound by a public tender contract, a 45-day stock-out can still trigger contractual consequences such as penalty clauses or default notices.

To bridge this gap, distributors should negotiate explicit supply continuity covenants into their distribution and OEM agreements as a matter of commercial practice:

For guidance on structuring comprehensive distributor qualification and onboarding agreements, refer to our framework on qualifying a circumcision device manufacturer or distributor programme and our evidence checklist for contract-manufactured sterile devices.

The downstream cascade ledger and compliance checklist

If a competent authority, a customer or a manufacturer asks how a notice was handled, 'we forwarded the email' is weak evidence. A standard downstream cascade ledger entry for each notice shows what was received, from whom, and when and to whom it was passed on.

To institutionalize this process, distributor quality managers should implement a six-step Standard Operating Procedure (SOP):

1. Intake & verification: Monitor a dedicated regulatory inbox. Decide whether the incoming document is the manufacturer's Article 10a information or a routine commercial message; if unclear, ask the sender in writing and keep the answer.
2. Recipient extraction: Query your Article 25(2) traceability records for every account supplied with the affected Basic UDI-DI or catalogue numbers within the lookback window defined in your SOP⁸.
3. Packet Assembly: Prepare the dispatch packet. Ensure the manufacturer's original notification is attached in full without modification. Draft an optional, clearly separated distributor cover letter if alternative devices are offered.
4. Auditable Dispatch: Send via secure, tracked electronic delivery (or registered mail where required by hospital procurement contracts), capturing automated delivery confirmations.
5. Ledger logging & archiving: Enter all transmission data in the downstream cascade ledger. Keep the records at least as long as you must be able to provide Article 25(2) traceability information, which is the Article 10(8) period of at least 10 years after the last device was placed on the market (15 years for implantable devices)⁸.
6. Clinical & Commercial Follow-up: Coordinate with affected hospital procurement officers to evaluate transition stock, schedule clinical in-servicing for replacement devices, and adjust standing purchase orders.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.

Its catalogue lists a CE-marked Auto-Circumcision Ring within an NMPA-registered disposable circumcision device platform. That listing does not by itself tell an EU distributor who the authorised representative is, how the device reaches the EU market or how supply notices would be routed. Those are questions to settle during qualification, for VEMERIX or any other non-EU supplier.

Before signing, ask a non-EU supplier for:

• Regulatory identity: The legal manufacturer and its EU authorised representative for each device you plan to distribute, and where the CE certificate and EUDAMED records can be checked. See verifying a CE certificate and its notified body and how an EU importer reads a missing EUDAMED device record.
• Article 10a procedure: The supplier's written procedure for Article 10a assessments and notifications, including which EU operators receive notices first and how quickly they are expected to pass them on.
• Notice contact: A named quality or regulatory contact for supply notices, separate from the sales contact.
• Commercial notice terms: Discontinuation and backorder notice periods for events outside Article 10a (Table 4), and any stock-holding commitment the supplier will put in writing.
• Quality-system evidence: VEMERIX describes its ISO 9001 and ISO 13485 systems on its quality page; certificates, registration documents and technical packs are supplied to qualified buyers on request through downloads or the contact form.

Frequently asked questions

Does a distributor have to give hospitals six months' notice of a discontinuation?
No. The six-month advance notification rule in the second subparagraph of MDR/IVDR Article 10a(1) applies to the legal manufacturer⁷. Distributors who receive an Article 10a notice are governed by Article 10a(3), which requires forwarding the notice without undue delay. If an upstream supplier provides only three months' notice due to unforeseen manufacturing constraints, the distributor's sole legal duty is to transmit that notice onward as soon as possible without intentional or negligent delay¹.

Is a 10-week backorder an Article 10a interruption?
Not necessarily. While Question 7 of Commission Q&A Rev.2¹ provides a general indication that an interruption is a temporary inability to supply expected to last more than 60 days, duration alone does not trigger Article 10a. The legal threshold requires that the disruption is reasonably foreseeable to result in serious harm or a risk of serious harm to patients or public health. Where the manufacturer has a successor device or bridging stock, or a suitable alternative is confirmed to meet expected demand, the Q&A says that in principle no notice is required^{1, 5}. A 10-week backorder of a commodity consumable with numerous market substitutes is managed as an operational backorder, not a statutory Article 10a event.

Can a distributor summarize the manufacturer's notice or add its own advice?
It should not change the notice itself. The Q&A expects operators not to change, add to or paraphrase the manufacturer's communication (questions 2 and 13)¹. Any advice, such as proposed alternatives, belongs in a separate, clearly distinguished cover note, and suitability of an alternative should be assessed with the customer's clinical team rather than asserted as equivalence.

Does Article 10a apply to legacy devices still sold under an MDD certificate?
Yes. Under MDR Article 120(13) and IVDR Article 110(11) (as amended by Regulation (EU) 2024/1860⁷), Article 10a also applies to legacy devices placed on the market pursuant to Directive 93/42/EEC (MDD) or Directive 90/385/EEC (AIMDD) under the transitional provisions, subject to the same serious-harm condition¹. Custom-made devices are the only category explicitly excluded from Article 10a.

Who notifies the competent authority when the manufacturer is in China?
When the legal manufacturer is located outside the European Union, Article 10a(1) requires the manufacturer to notify the Competent Authority of the Member State where its Authorised Representative (EC REP) is established¹. The manufacturer may have its EC REP, an importer or another party submit the MDCG 2024-16 form³, but legal responsibility remains with the manufacturer. Article 10a gives importers and distributors no filing duty of their own (Q&A questions 2 and 11).

Do we have to forward a notice for a device we stopped buying a year ago?
Probably not as a legal duty, and you may not receive one. Article 10a(3) covers those to whom you directly supply the device, and the Q&A (question 4) tells manufacturers that actors whose supply had already ceased are not impacted^{1, 7}. If you do receive a notice for a device you stopped buying recently, consider forwarding it to customers who bought it from you and may still hold stock, and record why you did or did not.